These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 2372514

  • 1. Studies of an oral iron chelator: 1,2-dimethyl-3-hydroxy-pyrid-4-one. I. Iron excretion in rats: development of a new rapid microwave method for iron analysis in faeces.
    Venkataram S, Rahman YE.
    Br J Haematol; 1990 Jun; 75(2):274-7. PubMed ID: 2372514
    [Abstract] [Full Text] [Related]

  • 2. Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.
    Kontoghiorghes GJ, Hoffbrand AV.
    Br J Haematol; 1986 Apr; 62(4):607-13. PubMed ID: 3964556
    [Abstract] [Full Text] [Related]

  • 3. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L.
    Br Med J (Clin Res Ed); 1987 Dec 12; 295(6612):1509-12. PubMed ID: 3122880
    [Abstract] [Full Text] [Related]

  • 4. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
    Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P.
    Br J Haematol; 1990 Oct 12; 76(2):295-300. PubMed ID: 2094333
    [Abstract] [Full Text] [Related]

  • 5. Studies on an oral iron chelator: 1,2-dimethyl-3-hydroxy-pyrid-4-one (DMHP). Mechanism of intestinal absorption in rabbits.
    Railkar AM, Awni WM, Camp RJ, Rahman YE.
    J Pharm Pharmacol; 1993 May 12; 45(5):400-5. PubMed ID: 8099956
    [Abstract] [Full Text] [Related]

  • 6. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
    Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, St Louis P, Freedman MH, McClelland RA, Templeton DM.
    Lancet; 1990 Nov 24; 336(8726):1275-9. PubMed ID: 1978115
    [Abstract] [Full Text] [Related]

  • 7. Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload.
    al-Refaie FN, De Silva CE, Wonke B, Hoffbrand AV.
    J Clin Pathol; 1995 Feb 24; 48(2):110-4. PubMed ID: 7745107
    [Abstract] [Full Text] [Related]

  • 8. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Feb 24; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 9. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
    Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G.
    Clin Pharmacol Ther; 1994 Jan 24; 55(1):70-5. PubMed ID: 8299320
    [Abstract] [Full Text] [Related]

  • 10. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
    Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G.
    N Engl J Med; 1995 Apr 06; 332(14):918-22. PubMed ID: 7877649
    [Abstract] [Full Text] [Related]

  • 11. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
    Wong CS, Kwok JC, Richardson DR.
    Biochim Biophys Acta; 2004 Dec 24; 1739(1):70-80. PubMed ID: 15607119
    [Abstract] [Full Text] [Related]

  • 12. Pharmaceutical analysis of the oral iron chelator deferiprone (DMHP,L1).
    Lange R, Lameijer W, Slijkhuis C, de Kaste D.
    Pharm World Sci; 1996 Aug 24; 18(4):142-7. PubMed ID: 8873230
    [Abstract] [Full Text] [Related]

  • 13. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
    Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV.
    Lancet; 1987 Jun 06; 1(8545):1294-5. PubMed ID: 2884415
    [Abstract] [Full Text] [Related]

  • 14. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Jun 06; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 15. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.
    Zevin S, Link G, Grady RW, Hider RC, Peter HH, Hershko C.
    Blood; 1992 Jan 01; 79(1):248-53. PubMed ID: 1728313
    [Abstract] [Full Text] [Related]

  • 16. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
    Kontoghiorghes GJ, Sheppard L, Hoffbrand AV, Charalambous J, Tikerpae J, Pippard MJ.
    J Clin Pathol; 1987 Apr 01; 40(4):404-8. PubMed ID: 3584483
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.
    Haematologica; 2003 Dec 01; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract] [Full Text] [Related]

  • 20. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G.
    Int J Clin Pharmacol Ther; 1996 Jul 01; 34(7):288-92. PubMed ID: 8832304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.